Get the Stockscreener App
3.42
0.29%
0.00
Dermata Therapeutics Inc stock is traded at $3.42, with a volume of 43,992.
It is up +0.29% in the last 24 hours and down -29.42% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$3.42
Open:
$3.42
24h Volume:
43,992
Relative Volume:
0.35
Market Cap:
$2.30M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.1597
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
-15.72%
1M Performance:
-29.42%
6M Performance:
-60.57%
1Y Performance:
-72.00%
1-Day Range:
$3.24
$3.4385
1-Week Range:
$3.24
$4.29
52-Week Range:
$3.24
$23.70
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
3.38 | 2.33M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.41 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.28 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.39 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.96 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.19 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Relative strength of Dermata Therapeutics Inc. in sector analysisJuly 2025 PostEarnings & Verified Chart Pattern Signals - newser.com
Has Dermata Therapeutics Inc. formed a bullish divergenceTrade Exit Summary & Safe Capital Growth Tips - newser.com
Heatmap analysis for Dermata Therapeutics Inc. and competitorsWeekly Profit Recap & AI Driven Price Predictions - newser.com
Is Dermata Therapeutics Inc. stock a bargain at current levelsJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
Can Dermata Therapeutics Inc. Equity Warrant stock resist market sell offsPortfolio Value Summary & Growth Oriented Trade Recommendations - newser.com
Institutional scanner results for Dermata Therapeutics Inc. Equity WarrantPortfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
What hedge fund activity signals for Dermata Therapeutics Inc. Equity Warrant stockQuarterly Profit Report & AI Driven Price Forecasts - newser.com
Is Dermata Therapeutics Inc. stock a buy on dips2025 Top Gainers & Low Risk Entry Point Guides - newser.com
Published on: 2025-11-02 14:36:23 - newser.com
Visualizing Dermata Therapeutics Inc. stock with heatmapsMarket Trend Report & Capital Efficiency Focused Strategies - newser.com
Statistical indicators supporting Dermata Therapeutics Inc.’s strengthInsider Buying & Fast Gain Stock Trading Tips - newser.com
Published on: 2025-11-02 05:58:24 - newser.com
What data driven models say about Dermata Therapeutics Inc.’s futureTrend Reversal & Expert Approved Momentum Ideas - newser.com
Is Dermata Therapeutics Inc. stock supported by innovation pipelinePortfolio Risk Summary & Fast Moving Trade Plans - newser.com
What Fibonacci levels say about Dermata Therapeutics Inc. reboundEarnings Miss & Community Supported Trade Ideas - newser.com
Intraday pattern recognizer results for Dermata Therapeutics Inc. Equity Warrant2025 Earnings Surprises & Stock Portfolio Risk Control - newser.com
What analysts say about Dermata Therapeutics Inc Equity Warrant stockStochastic Oscillator Alerts & Superior Wealth Growth - earlytimes.in
Risk adjusted return profile for Dermata Therapeutics Inc. analyzed2025 Growth vs Value & Weekly Market Pulse Updates - newser.com
Order flow analysis tools used on Dermata Therapeutics Inc.2025 Analyst Calls & Weekly High Return Forecasts - newser.com
Will Dermata Therapeutics Inc. stock outperform Nasdaq indexRate Cut & High Accuracy Trade Signal Alerts - newser.com
What valuation multiples suggest for Dermata Therapeutics Inc. Equity Warrant stockDip Buying & Stepwise Trade Signal Implementation - newser.com
Why Dermata Therapeutics Inc. stock is trending among retail tradersWeekly Gains Summary & Weekly Sector Rotation Insights - newser.com
Trend analysis for Dermata Therapeutics Inc. Equity Warrant this weekGlobal Markets & Weekly Momentum Stock Picks - newser.com
Published on: 2025-10-31 05:03:00 - newser.com
Can technical indicators confirm Dermata Therapeutics Inc.’s reversalTrade Risk Summary & Free Growth Oriented Trading Recommendations - newser.com
Published on: 2025-10-31 03:32:32 - newser.com
Applying Elliott Wave Theory to Dermata Therapeutics Inc.July 2025 PostEarnings & Weekly High Return Opportunities - newser.com
Is Dermata Therapeutics Inc. Equity Warrant building a consolidation baseQuarterly Portfolio Summary & Target Return Focused Picks - newser.com
Analyzing drawdowns of Dermata Therapeutics Inc. with statistical tools2025 Market Sentiment & Community Driven Trade Alerts - newser.com
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):